A series of articles will be published on the management of irAE. For members only. Register now and get full access. It’s free!

U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

US FDA approved immune-checkpoint inhibitors updated 09-Mar-2019

Know all the United States Food and Drug Administration (U.S. FDA) approved immune-checkpoint inhibitors. Members of MediPaper can download the free PPT slides summarising the U.S. FDA approved immune-checkpoint inhibitors and other U.S. FDA approved immunotherapies.

U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer
Dr Joanne Chiu HKU management irAE hepatitis manage immune-mediated hepatitis immunotherapy I-O immunooncology immune-induced hepatitis

Management of Immune-Mediated Hepatitis: a Case Report

There is no excerpt because this is a protected post.

Dr Joanne Chiu HKU management irAE hepatitis manage immune-mediated hepatitis immunotherapy I-O immunooncology immune-induced hepatitis

ImmunoOncology: Dr Oscar Chan on the treatment of irAE rash

There is no excerpt because this is a protected post.

immuno-oncology I-O treatment for the irAE Rash
Prof Stefan Kasper on I-O in EXTREME-ineligible Head and Neck Cancer I-O in SCCHN with focus on EXTREME-ineligible Patients and the future directions of combination immunotherapy

Prof Stefan Kasper on I-O in EXTREME-ineligible SCCHN

There is no excerpt because this is a protected post.

Prof Stefan Kasper on I-O in EXTREME-ineligible Head and Neck Cancer I-O in SCCHN with focus on EXTREME-ineligible Patients and the future directions of combination immunotherapy

I-O in Special Populations: the Treatment of Immunotherapy-Induced Pneumonitis

There is no excerpt because this is a protected post.

Adrian TSE HKIOC irAE pneumonitis lung immunotherapy-induced pneumonitis I-O Immuno-Oncology cannonball metastases cancer
Herbert Loong on irAEs Immunotherapy (I-O) and New Onset Diabetes or immune-mediated diabetes

I-O in Special Populations: Diabetes and Concomitant Steroids

There is no excerpt because this is a protected post.

Herbert Loong on irAEs Immunotherapy (I-O) and New Onset Diabetes or immune-mediated diabetes
Nivolumab Renal Cell Cancer Symposium Highlight

Nivolumab for Renal Carcinoma: Getting the Most Out of PD-1 Immunotherapy

There is no excerpt because this is a protected post.

Nivolumab Renal Cell Cancer Symposium Highlight